Cell Therapy Cryogenics - Moving Beyond the DMSO Era

Explore advanced cryopreservation technologies in this 37-minute webinar that addresses critical limitations of dimethyl sulfoxide (DMSO) in cell therapy manufacturing and introduces innovative peptoid-based alternatives. Learn about the significant challenges DMSO poses in large-scale commercial cell therapy production, including cytotoxicity, variable recovery rates, poor compatibility with serum-free processes, and adverse effects on patients and cellular integrity. Discover how DMSO causes acute toxicity, irreversible chromosome damage, and epigenetic alterations that compromise therapeutic quality and limit scalability. Examine X-Therma's XT-Thrive® technology, a next-generation cryopreservation solution inspired by natural antifreeze proteins that offers a chemically defined, cGMP-grade alternative free of DMSO, serum, and proteins. Understand how this peptoid-based technology integrates seamlessly into existing workflows while eliminating bottlenecks associated with long hold times and wash-out steps required by traditional methods. Review independent study results demonstrating XT-Thrive®'s superior performance across multiple cell types, including mesenchymal stromal cells (MSCs), T-cells, organoids, and tissues, showing significantly higher post-thaw viability, proliferation, and functionality compared to conventional media. Analyze how MSCs preserved with XT-Thrive® maintain genomic stability and tri-lineage differentiation capacity while T-cells retain cytotoxicity and phenotype characteristics. Learn about the technology's unique advantage of allowing cells to remain stable at room temperature for extended periods, facilitating easier handling during filling, transport, and clinical administration. Gain insights into how this breakthrough technology removes DMSO constraints and sets new benchmarks for safe, reliable, and scalable biopreservation as cell and gene therapy manufacturing advances toward industrial scale and serum-free systems. The presentation is delivered by Dr. Steve Oh, who brings over 35 years of international biotechnology experience, 43 patents, 150 publications, and leadership of over $34M in research funding to provide expert perspective on the future of cryopreservation in regenerative medicine.